The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

NCT02287415 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: BIA 2-093
DRUG: Warfarin

Sponsor

Bial - Portela C S.A.